drug-related adverse reaction leading to caspofungin discontinuation was The printed package leaflet of the medicinal product must state the name and. CANCIDAS® is a sterile, lyophilised product for intravenous infusion that contains a Interpretive standards (or breakpoints) for caspofungin against Candida. CANCIDAS* is a sterile, lyophilized product for intravenous (IV) infusion that CANCIDAS is the first of a new class of antifungal drugs (glucan synthesis.
|Published (Last):||7 March 2015|
|PDF File Size:||4.37 Mb|
|ePub File Size:||6.87 Mb|
|Price:||Free* [*Free Regsitration Required]|
For the treatment of Aspergillus osteomyelitis or infectious arthritis in patients who are refractory to or intolerant of other antifungal therapies. Supplemental dosing is not required following hemodialysis.
Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment.
Administering inducers of hepatic cytochrome P, such as efavirenz, concurrently with caspofungin may reduce the plasma concentrations of caspofungin. The pathway of chemical degradation is uncertain. For endocarditis, treat for at least 6 weeks after valve replacement.
Dosage and administration 2. Growth of Candida sp. Because of canxidas risk of relapse of oropharyngeal candidiasis in patients with HIV infections, suppressive oral therapy could be considered [see see package insert Clinical Studies Longer courses greater than 6 months are frequently necessary.
Morphologically, fungi hyphae and yeast shapes are altered.
Cancidas (caspofungin acetate) dose, indications, adverse effects, interactions from
Aspergillosis clinical practice inert suggest caspofungin as a first line empiric therapy. The reductions may be clinically significant. Studies to evaluate the effects of cancidsa on a breast-fed infant have not been conducted; however, based on caspofungin’s poor oral absorption, the risks appear to be low.
Do not administer as an IV bolus injection. For the treatment of invasive aspergillosis in patients who are refractory to or intolerant of other antifungal therapies.
Theoretically, rifabutin and rifapentine could also decrease caspofungin blood concentrations.
Caspofungin Acetate for Injection Now Available from Fresenius Kabi
It has no activity against Cryptococcus neoformans, but in vitro has shown synergistic activity against C. Do not use any diluents containing dextrose to prepare caspofungin. Caspofungin can cause abnormalities in liver enzymes. For the treatment of bone and joint infections, including osteomyelitis and infectious insett. Visually inspect prepared infusions for particulate matter and discoloration prior to administration.
A single mg loading dose should be administered on Day 1, followed by 50 mg daily thereafter. Consider intravascular catheter removal.
If the mg dose is well tolerated but does not provide an adequate clinical response, the daily dose can be increased to 70 mg. However, site of infection, local susceptibility patterns, and specific microbial susceptibility should be assessed before choosing an alternative agent.
Caspofungin Acetate for Injection Now Available from Fresenius Kabi – Fresenius Kabi USA
For the treatment of intraabdominal aspergillosis in patients who are refractory to candidas intolerant of other antifungal therapies. Caspofungin does not interact substantially with the cytochrome P enzyme system, but does undergo significant hepatic metabolism.
However, where recommended, a mg loading dose should still be innsert on Day 1. Caspofungin should be used in pregnancy only when the benefits clearly outweigh the risks.
Monitor potentially exposed infants for gastrointestinal adverse events and signs of histamine release. There have been no well-controlled studies in pregnant women. Monitor patients who develop abnormal liver function tests LFTs during concomitant use with Caspofungin.
In general, antifungal therapy should continue for at least 14 days after the last positive culture.